eISSN: 2345-6558

Free Access

Journal of Parathyroid Disease 2016;4(1):3-6
Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial

Original

Heshmatollah Shahbazian 1, Mohammad-Reza Tamadon 2, Seyed Karim Mowla 3, Shokouh Shayanpour 3 * , Fatemeh Hayati 4, Melika Shojaii 5, Leila Yazdanpanah 6

1 Department of Nephrology, Golestan Hospital, Chronic Renal Failure Research Center, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
2 Department of Nephrology, Semnan University of Medical Sciences, Semnan, Iran.
3 Department of Rheumatology, Golestan Hospital, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
4 Department of Nephrology, Imam Khomeini Hospital, Chronic Renal Failure Research Center, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
5 Department of Internal Medicine, Golestan Hospital, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
6 Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


*Corresponding author: Shokouh Shayanpour,
Email: Dr.shayanpour@yahoo.com


Abstract

Introduction: With decline of glomerular filtration rate (GFR), a number of metabolic bone diseases such as osteoporosis are  simultaneously caused. We evaluated the results of alendronate on bone density in patients with chronic kidney disease (CKD).

Objectives: The main aim of the study was evaluation of the changes in bone density, one year after treatment by dual energy x-ray absorptiometry technique.

Patients and Methods: We evaluated two treatment regimens on bone density of 44 patients between 18-45 years old (22 in experimental and 22 in control group) in a controlled double blind randomized trial. The experimental group was prescribed alendronate (10 mg), calcitriol (0.25 μg) and calcium carbonate (1500 mg) daily. The control group was treated with the same regimen except for alendronate.

Results: After completion of the trial, bone density decreased in all patients in the control group, but increased in the experimental group, in lumbar spine and femoral neck, 6.4% and 4.5% respectively. Alendronate was well tolerated.

Conclusion: Alendronate is safe in these patients and increases the bone density in CKD stage 1 and 2. Keywords: Alendronate; Bone density; Chronic kidney disease



Notes

Implication for health policy/practice/research/ medical education

In a study on 44 chronic kidney disease (CKD) patients, we found that alendronate is a safe and effective agent for treatment of osteoporosis in CKD of stages I and II.  

Please cite this paper as: Shahbazian H, Tamadon MR, Mowla SK, Shayanpour Sh, Hayati F, Shojaii M, et al. Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial. J Parathyr Dis. 2016;4(1):3-6.

 

 


Comments
First name  
Last name  
Email address  
Comments  
Security code



Article
PDF


Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks

Cite by
Google Scholar

Google Scholar
Articles by Heshmatollah Shahbazian
Articles by Mohammad-Reza Tamadon
Articles by Seyed Karim Mowla
Articles by Shokouh Shayanpour
Articles by Fatemeh Hayati
Articles by Melika Shojaii
Articles by Leila Yazdanpanah
Similar articles
Related articles

PubMed
Articles by Heshmatollah Shahbazian
Articles by Mohammad-Reza Tamadon
Articles by Seyed Karim Mowla
Articles by Shokouh Shayanpour
Articles by Fatemeh Hayati
Articles by Melika Shojaii
Articles by Leila Yazdanpanah


Article Access Statistics
Viewed
PDF Downloaded
Comments

Share this article!
Creative Commons Attribution 4.0 License This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 The Author(s)
Published by Nickan Research Institute